Acrongenomics and Molecular Vision: Fully Functional Multi-Channel Prototype Device Undergoing Internal Validation.
Thursday April 10, 9:00 am ET
Acrongenomics Inc. (AGNM: OTCBB), today announces that it is fully committed to the joint collaboration contract in partnership with Molecular Vision.
Molecular Vision states that the latest iteration of the technology is currently being tested as part of the on-going research and development agreement. In one simple step, the fully functional, multi-channel device will be used to simultaneously measure both Creatinine and Vitamin C directly from a urine sample. It is anticipated that this device will be presented to an external audience in the coming weeks.
Furthermore progress continues to be made in the detection of myoglobin, a cardiac biomarker. In keeping with the development timelines this assay will be tested with human blood samples in the near future, reaching another milestone in the evolution of this proprietary detection technology.
About Acrongenomics:
Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its headquarters in Geneva, Switzerland.
About Molecular Vision:
Molecular Vision is an Imperial College spin-out company that develops low-cost diagnostic devices for use in the doctor's surgery and in the home. Its proprietary devices combine microfluidic chips with organic-semiconductor light-sources and photodetectors to provide lab-quality diagnostic tests in a miniaturised, easy-to-use, disposable format.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates", "believes", "could", "expects", "intends", "may", "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions. For further information concerning risks and uncertainties that may affect our future results, please review the disclosures contained in our latest filings with the SEC, including our most recent annual report on Form 10-KSB, and subsequent quarterly reports on Form 10-QSB. Other than as required by federal securities laws, we undertake no obligation to publicly update or revise any of our forward-looking statements, whether as a result of changed circumstances, new information, future events, or for any other reason occurring after the date of this news release.
